首页> 外文期刊>Multiple sclerosis: clinical and laboratory research >Personalised medicine for multiple sclerosis care
【24h】

Personalised medicine for multiple sclerosis care

机译:用于多发性硬化症护理的个性化药物

获取原文
获取原文并翻译 | 示例
           

摘要

Treatments with a range of efficacy and risk of adverse events have become available for the management of multiple sclerosis (MS). However, now the heterogeneity of clinical expression and responses to treatment pose major challenges to improving patient care. Selecting and managing the drug best balancing benefit and risk demands a new focus on the individual patient. Personalised medicine for MS is based on improving the precision of diagnosis for each patient in order to capture prognosis and provide an evidence-based framework for predicting treatment response and personalising patient monitoring. It involves development of predictive models involving the integration of clinical and biological data with an understanding of the impact of disease on the lives of individual patients. Here, we provide a brief, selective review of challenges to personalisation of the management of MS and suggest an agenda for stakeholder engagement and research to address them.
机译:对于多发性硬化症(MS)的管理,具有一系列疗效和不良事件风险的治疗。 然而,现在临床表达的异质性和对治疗的反应构成改善患者护理的主要挑战。 选择和管理药物最佳平衡福利和风险要求对个体患者进行新的重点。 MS的个性化医学是基于提高每位患者的诊断精度,以捕获预后并提供基于证据的框架,用于预测治疗响应和个性化患者监测。 它涉及发展涉及临床和生物数据整合的预测模型,了解疾病对个体患者的生命的影响。 在这里,我们对对MS管理的个性化的挑战进行了简短的,选择性地审查,并提出了利益攸关方参与和研究的议程来解决这些问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号